LHRH in prostate cancer treatment: From Hypothalamic Discovery to Clinical Translation

INTRODUCTION & OBJECTIVES: This project elucidates the pivotal scientific discoveries that culminated in the isolation of luteinizing hormone-releasing hormone (LH-RH). It details the contributions of scientists Andrew Schally and Roger Guillemin, whose competitive biochemical research led to the Nobel Prize in 1977. MATERIALS & METHODS: This project entails a comprehensive review of the pivotal scientific developments that culminated in the discovery of LHRH, examined through the historical lens. The sources included peer-reviewed articles, Nobel lectures, and oral history transcripts. RESULTS: G.W. Harris first showed the anterior pituitary's regulation by the hypothalamus in 1937, establishing the principles for Schally and Guillemin. Schally and Guillemin independently isolated TRF in 1969, requiring 160,000 porcine hypothalami for purification. Both then pursued LHRH, isolating it independently in 1971 using 240,000 porcine brains and developing advanced biochemical techniques. These methods have enabled LHRH analog synthesis for prostate cancer research. In 1971, Schally demonstrated that LHRH could suppress gonadotropin secretion. Synthetic LHRH infusion in monkeys showed LHRH's ability to desensitize pituitary GnRH receptors. This discovery enabled the use of LHRH analog treatments for hormone-sensitive conditions. Schally conducted the first clinical trials in Mexico in 1972 and organized the first LHRH agonist study for prostate cancer, which was published in 1982. CONCLUSIONS: The discovery of LHRH represents a landmark convergence of evolving physiological concepts, rigorous biochemical innovation, and impactful clinical translation, leading to the Nobel Prize. The rivalry between Schally and Guillemin led to foundational discoveries that transformed the management of androgen-dependent malignancies.